Cerus (NASDAQ:CERS) CFO Sells $113,763.50 in Stock

Cerus Corporation (NASDAQ:CERS) CFO Kevin Dennis Green sold 55,225 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $2.06, for a total transaction of $113,763.50. Following the completion of the transaction, the chief financial officer directly owned 1,195,891 shares in the company, valued at $2,463,535.46. This trade represents a 4.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Kevin Dennis Green also recently made the following trade(s):

• On Friday, March 6th, Kevin Dennis Green sold 27,796 shares of Cerus stock. The shares were sold at an average price of $2.01, for a total value of $55,869.96.

Cerus Stock Performance

CERS opened at $1.93 on Tuesday. The stock’s 50 day moving average price is $2.31 and its 200-day moving average price is $1.86. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.17 and a current ratio of 1.73. Cerus Corporation has a one year low of $1.12 and a one year high of $2.96. The stock has a market cap of $370.89 million, a price-to-earnings ratio of -24.13 and a beta of 1.51.

Cerus (NASDAQ:CERS) last posted its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The business had revenue of $64.58 million for the quarter, compared to the consensus estimate of $59.31 million. On average, equities analysts forecast that Cerus Corporation will post -0.08 EPS for the current year.

Institutional Trading of Cerus

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors grew its position in shares of Cerus by 15.3% in the fourth quarter. Captrust Financial Advisors now owns 37,051 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 4,916 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in Cerus by 8.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 81,556 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 6,094 shares in the last quarter. Engineers Gate Manager LP grew its position in shares of Cerus by 4.7% during the 4th quarter. Engineers Gate Manager LP now owns 142,958 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 6,415 shares during the last quarter. Intech Investment Management LLC boosted its stake in Cerus by 8.6% during the 3rd quarter. Intech Investment Management LLC now owns 93,343 shares of the biotechnology company’s stock valued at $148,000 after purchasing an additional 7,355 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Cerus by 68.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 7,603 shares during the period. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Cerus

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Institutional accumulation: several funds materially increased or initiated positions (AQR, Millennium, Cubist among others), signaling professional investor interest that can support the stock over time.
• Neutral Sentiment: Analyst coverage mixed: TD Cowen has maintained a buy stance while at least one service downgraded Cerus from buy to hold — mixed signals that may limit a clear directional catalyst from the Street.
• Neutral Sentiment: Short‑interest print appears unreliable: a March 9 short‑interest note shows 0 shares and 0.0 days‑to‑cover — likely a reporting or data issue. Treat this as noise until exchanges correct filings.
• Negative Sentiment: Heavy insider selling: multiple executives and directors disclosed sales March 5–9 that meaningfully reduced their holdings (CEO William Greenman sold ~78,187 shares; Director Richard J. Benjamin reported multiple sales; COO Vivek Jayaraman ~34,094; CFO Kevin D. Green ~27,796; plus other insider transactions). The clustered sales (each at roughly $1.88–$2.06) increase float and can weigh on near‑term sentiment even if sales are for personal liquidity. Source example: InsiderTrades coverage of recent filings. Cerus insider selling article
• Negative Sentiment: Analyst downgrade pressure: at least one service downgraded Cerus from buy to hold recently, which can amplify negative reaction to insider sales and slow buying from retail investors.

Analyst Ratings Changes

Several brokerages recently commented on CERS. Wall Street Zen lowered shares of Cerus from a “buy” rating to a “hold” rating in a report on Saturday. TD Cowen restated a “buy” rating on shares of Cerus in a report on Monday, January 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.